

TABLE 1. Percent Sanguinarine Iminium Ion versus pH as Analyzed by Hplc

pH	Day 1	Day 7	Day 49	Day 91	Day 120 ^a
3.5	97.4	98.2	100.8	96.8	90.3
4.0	93.8	94.1	90.6	86.5	90.3
5.0	92.0	95.3	97.4	84.0	96.0
5.4	100.0	93.7	100.0	94.8	93.0
6.0	87.9	72.2	61.3	72.2	90.6
6.6	41.1	30.3	28.5	33.6	97.5
7.0	5.0	4.8	4.0	3.7	95.8
7.6	1.5	2.0	1.7	1.2	95.8
9.8	0.7	1.9	0.9	0.9	104.5
11.9	0.4	0.4	0.3	0.2	108.1

^aSamples were acidified to pH 3.5 with H₃PO₄ and analyzed by the hplc method described.

with a mobile phase of MeOH-H₂O (84:16) with 5 mM triethylamine buffered to pH 5.4 with H₃PO₄ at a flow rate of 0.5 ml/min. A Waters 440 absorbance detector at 280 nm was used to analyze for sanguinarine. A 5-ml aliquot of the solution was removed and centrifuged. The supernatant from the pH solutions was removed and acidified with one drop of concentrated H₃PO₄. A 20- μ l injection was used and quantitation was made by comparison with a sanguinarine standard solution.

RESULTS AND DISCUSSION

Analysis by uv absorption spectroscopy and hplc (Table 1) indicated that below pH 5.4 the iminium ion form of sanguinarine was the dominant form. Sanguinarine solutions at pH greater than 5.4 had decreased concentrations of the iminium ion. The conversion to the alkanolamine was essentially complete at pH 7.0. At pH 9.8, the concentration of the iminium ion was less than 1% of its concentration at pH 3.5. Solutions were analyzed at days 7, 49, and 91 and found to contain the iminium ion at the same concentration determined at day 1.

As the concentration of iminium ion decreased with increasing pH, a white precipitate was observed in the solutions. The quantity of the white precipitate in these solutions was correlated directly with the loss of iminium ion detected by uv spectroscopy and hplc. The white precipitate was identified by nmr in DMSO-*d*₆ as the alkanolamine by substitution at the α -carbon and was shown to be insoluble in either H₂O or

EtOH. This is consistent with the formation of the alkanolamine reported (13). The alkanolamine could be either the 6-hydroxysanguinarine or the pseudoethanolate sanguinarine. The alkanolamine form is dependent on the solubility product of the compound in a solution of H₂O/EtOH.

At day 120, all samples were acidified to pH 3.5 with H₃PO₄ and analyzed by hplc (Table 1). Analysis of the solutions indicated almost complete recovery of the sanguinarine iminium ion concentrations at pH 3.5. Recovery of the iminium ion form of sanguinarine was 96.2 \pm 6%. Therefore, disproportionation of any alkanolamine in solution by oxygen to oxysanguinarine and dihydrosanguinarine at pH values above 6 was not observed in this system. These data confirm the results observed by Maiti on the stability of the alkanolamine (14).

Figure 2 is a plot of the concentration of sanguinarine iminium ion form versus pH at days 1 and 91. No significant loss of the iminium ion from these solutions was detected over this time period. The variations in the measured iminium ion concentrations were within the hplc experimental error.

Solutions of sanguinarine chloride in H₂O/EtOH without buffers analyzed as 100% iminium ion at pH 5.4. The observed shift in equilibrium to the alkanolamine occurred as the pH was in-




FIGURE 2. Concentration of sanguinarine iminium ion form versus pH at days 1 and 91 as analyzed by hplc.

creased with citrate and NaOH solutions. Near complete recovery of the iminium ion from solutions buffered above pH 5.4 was demonstrated when these H₂O/EtOH solutions were acidified to pH 3.5. These results indicate that sanguinarine is stable in a solution of H₂O/EtOH from pH 3.5 to 11.9.

ACKNOWLEDGMENTS

The authors wish to acknowledge the expert technical assistance of B.J.B. Jones and H.H. Barnes.

LITERATURE CITED

1. F.R. Stermitz, K.A. Larsen, and D.K. Kim, *J. Med. Chem.*, **16**, 939 (1973).
2. F.R. Stermitz, J.D. Gillespie, L.S. Amoros, R. Romero, T.A. Stermitz, K.A. Larsen, S. Early, and J.E. Ogg, *J. Med. Chem.*, **18**, 708 (1975).
3. H.G. Cohen, K.D. Straub, C. Tiefenback, E.E. Seifen, and F.R. Stermitz, *Biochem. Pharmacol.*, **27**, 2555 (1978).
4. G.A. Cordell and N.R. Farnsworth, *Lloydia*, **40**, 1 (1977).
5. J.L. Dzink and S.S. Socransky, *Antimicrob. Agents Chemother.*, **27**, 663 (1985).
6. K.S. Cowen, S. Sakamoto, M. Sakamoto, and G.L. Southard, *Comp. Cont. Ed. Dent.*, Supplement No. 7, (1986).
7. P.M. Cala, J.G. Norby, and D.C. Tosteson, *J. Membrane Biol.*, **64**, 23 (1982).
8. K.D. Straub and P. Carver, *Biochem. Biophys. Res. Commun.*, **62**, 913 (1975).
9. B.J. Pitts and R. Meyerson, *Drug. Develop. Res.*, **1**, 43 (1981).
10. M.A. Caolo and F.R. Stermitz, *Heterocycles*, **12**, 11 (1979).
11. L.A. Mitscher, Y.H. Park, D. Clark, and G.W. Clark, *J. Nat. Prod.*, **41**, 145 (1978).
12. E.M. Thorne, R.T. Boulware, R.J. Harkrader and G.L. Southard, *J. Soc. Cosmet. Chem.*, **37**, 279 (1986).
13. V. Simanek and V. Preininger, *Heterocycles*, **6**, 475 (1977).
14. M. Maiti, R. Nandi, and K. Chaudhuri, *Photochem. Photobiol.*, **38**, 245 (1983).

Received 20 March 1986